Theralase CEO Interviewed by CBC TV about Progress in Anti-Cancer and Pain Research
June 05 2014 - 5:59AM
Access Wire
Roger Dumoulin-White talks to
Amanda Lang about Theralase's strategy to deliver value to
shareholders and patients
Toronto, Ontario / ACCESSWIRE / June 5,
2014 / Theralase Technologies Inc.
("Theralase") (TSXV: TLT)
(TLTFF: OTCBB) announced today that CBC's senior
business correspondent and anchor on The Lang and O'Leary Exchange,
Amanda Lang, interviewed Theralase President and CEO, Roger
Dumoulin-White about the Company and how the Company is breaking
significant new ground in anti-cancer and pain management
technology.
Link to the show:
http://www.cbc.ca/revenuegroup/the-lang-oleary-exchange.html
Roger Dumoulin-White,
President and CEO of Theralase, stated, "My appearance on Canada's
top business program confirms that Theralase is emerging as a major
research and manufacturing company in two of the most important
sectors of the healthcare industry - seeking a cure for cancer and
alleviating pain. It is estimated that $91 Billion is spent on the
war on cancer and $100 Billion on pain in the United States,
annually.
For the last 20 years,
Theralase has designed and manufactured patented therapeutic laser
technology, which is used for the elimination of pain, reduction of
inflammation and dramatic acceleration of tissue healing. Theralase
has sold over 800 systems in Canada and over 400 systems in the US
and international markets to licenced healthcare practitioners such
as: medical doctors, chiropractors, physical therapists and
athletic therapists.
Theralase has been so
successful in healing nerve, muscle and joint conditions in
clinical practice that Theralase's scientists decided to
investigate a new application for lasers, the destruction of
cancer. Theralase's anti-cancer technology focuses on using
specially designed molecules called Photo Dynamic Compounds or PDCs
that are able to localize to the DNA of cancer cells and then, when
activated by light, destroy the cancer cells.
Theralase recently completed
research that demonstrated that its PDC technology is not only able
to destroy the primary tumour, but also discovered a "memory
response" for the technology. In these animal studies, once the
primary tumour was destroyed, repeated injections of cancer cells
at a few weeks post-treatment, or even 10 months post-treatment,
did not generate cancerous tumours and in fact prevented the
recurrence of cancer.
Roger Dumoulin-White,
President and CEO of Theralase, stated, "Amanda Lang is extremely
knowledgeable and understood the application and benefits of
Theralase's therapeutic laser and anti-cancer technology for both
the elimination of pain and the destruction of cancer,
respectively. Our therapeutic laser technology has been clinically
proven to eliminate pain, reduce inflammation and accelerate tissue
repair, healing millions of patient's nerve, muscle and joint
conditions, effectively. We are very excited about the
possibilities for Theralase's anti-cancer technology. If it shows
the same efficacy in humans that it has in animals, then our PDC
anti-cancer technology and the implications of this "memory
response" discovery are nothing short of game changing for both
Theralase and for cancer patients."
About The Lang and O'Leary
Exchange:
The Lang and O'Leary
Exchange is a Canadian
business news television series, which airs weekdays
on CBC
Television and CBC News
Network. Hosted by CBC's senior business
correspondent Amanda Lang and
entrepreneur/investor
Kevin
O'Leary, the series presents a summary of the
day's major business stories in a manner similar to Lang and
O'Leary's earlier Business News Network
series SqueezePlay.
About Theralase Technologies Inc.
Founded in 1994,
Theralase Technologies Inc. ("Theralase") (TSXV:
TLT) (TLTFF: OTCBB) designs, manufactures and markets
patented superpulsed laser technology used in eliminating pain and
destroying cancer. Theralase technology is safe and effective in
eliminating pain, reducing inflammation and accelerating tissue
regeneration of numerous nerve, muscle and joint conditions.
Theralase is actively developing patented technology that is able
to target and destroy cancers, bacteria and viruses when activated
by light.
Additional information is
available at www.theralase.com and
www.sedar.com .
This press release contains
forward-looking statements, which reflect the Company's current
expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual results could
differ materially from those projected herein. The Company
disclaims any obligation to update these forward-looking
statements.
Neither TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchanges) accepts responsibility for
the adequacy or accuracy of this release.
For More Information:
Roger Dumoulin-White
President & CEO, Theralase Technologies
Inc.
416-629-5356
rwhite@theralase.com
Melony Jamieson
Get it Done Inc.
416-518-6355
melony@getitdone.ca
SOURCE: Theralase Technologies Inc.
Theralase Technologies (TSXV:TLT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Theralase Technologies (TSXV:TLT)
Historical Stock Chart
From Sep 2023 to Sep 2024